Genetic Determined Downregulation of Both Type 1 and Type 2 Cytokine Pathways Might Be Protective against Pancreatic Cancer

Authors

  • Letizia Scola,

    1. Cattedra di Patologia Clinica
    2. Gruppo di Studio sull’Immunosenescenza, General Pathology Section, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Corso Tuköry, Palermo, Italy
    Search for more papers by this author
  • Antonio Giacalone,

    1. Cattedra di Medicina Interna, Dipartimento di Medicina Clinica e delle Patologie Emergenti—University of Palermo, Via del Vespro Palermo, Italy
    Search for more papers by this author
  • Lorenzo Marasà,

    1. U.O.C. di Anatomia Patologica, Azienda di Rilievo Nazionale e di Alta Specializzazione Ospedali Civico Benfratelli, Ascoli, Di Cristina, Palermo, Italy
    Search for more papers by this author
  • Monica Mirabile,

    1. Cattedra di Patologia Clinica
    2. Gruppo di Studio sull’Immunosenescenza, General Pathology Section, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Corso Tuköry, Palermo, Italy
    Search for more papers by this author
  • Loredana Vaccarino,

    1. Cattedra di Patologia Clinica
    2. Gruppo di Studio sull’Immunosenescenza, General Pathology Section, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Corso Tuköry, Palermo, Italy
    Search for more papers by this author
  • Giusi Irma Forte,

    1. Cattedra di Patologia Clinica
    2. Gruppo di Studio sull’Immunosenescenza, General Pathology Section, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Corso Tuköry, Palermo, Italy
    Search for more papers by this author
  • Lydia Giannitrapani,

    1. Cattedra di Medicina Interna, Dipartimento di Medicina Clinica e delle Patologie Emergenti—University of Palermo, Via del Vespro Palermo, Italy
    Search for more papers by this author
  • Calogero Caruso,

    1. Gruppo di Studio sull’Immunosenescenza, General Pathology Section, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Corso Tuköry, Palermo, Italy
    Search for more papers by this author
  • Giuseppe Montalto,

    1. Cattedra di Medicina Interna, Dipartimento di Medicina Clinica e delle Patologie Emergenti—University of Palermo, Via del Vespro Palermo, Italy
    Search for more papers by this author
  • Domenico Lio

    1. Cattedra di Patologia Clinica
    2. Gruppo di Studio sull’Immunosenescenza, General Pathology Section, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Corso Tuköry, Palermo, Italy
    Search for more papers by this author

Address for correspondence: Prof. Domenico Lio, Chair of Clinical Pathology, Immunosenescence Study Group, General Pathology Section, Department of Pathobiology and Biomedical Methodologies, University of Palermo, Corso Tuköry 211, 90134 Palermo, Italy. Voice: +39-091-655-5913; fax: +39-091-655-5933. dolio@unipa.it

Abstract

Many cytokine polymorphisms have been studied for associations with susceptibility to breast, gastric, liver, lung, prostate, and ovarian cancer without conclusive results. The cytokine network, indeed, is characterized by complex interactions, and the final biological effect of a single genetic variation depends on the balance among different molecular signals. As is well known, Th1/Th2 cytokine unbalanced production might predispose to different pathologies, cancer included. In general, a prolonged type 1 inflammatory response might allow that cells accumulating enough “genetic hits” are promoted to neoplastic transformation. On the other hand, IL-13-producing cells through the IL-13/IL-4 receptor-alpha (R-α) pathway might facilitate escape from tumor immunosurveillance. Here are reported data on the evaluation of the influence of some type 2 and type 1 cytokine genetic polymorphisms as risk factors for pancreatic cancer. There was no overall association between pancreatic cancer risk and single cytokine SNPs. On the other hand, in evaluating the influence of combined cytokine genotypes we found that the combined IL-10-1082GA heterozygous and IL-4 Rα-1902AA homozygous genotype is underrepresented in the pancreatic cancer subject group. As is well known, the IL-10-1082GA genotype is associated with an intermediate production of this regulatory cytokine, whereas the IL-10-1902AA genotype of the IL-4Rα gene is associated with a reduced efficiency in signal transduction when the receptor is engaged by IL-13 or IL-4. These results strongly suggest that a genetic background associated to a mild downregulation of type 1 and type 2 inflammatory signals might be protective against pancreatic cancer.

Ancillary